Cullinan Therapeutics
Oncology Therapeutics · Health Care
Overview
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. See how.
Funding and backers
Backers
6
Helmholtz, Foresite Capital
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 2024
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
LAV Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune…
About Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and…
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
ImmuneSensor Therapeutics | Harnessing the innate immune system to treat inflammation, autoimmune disease and cancer.
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
MPM BioImpactVia a fund
Taiho VenturesVia a fund
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
Foresite CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Report
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipa
Read more
Report
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA an...
Read more
Report
Cullinan Therapeutics Outlines Q4 Milestones For T Cell Engager Pipeline
Cullinan Therapeutics (CGEM) outlined Q4 2026 milestones for its T cell engager pipeline. Velinotamig multi-dose SLE data will be presented at ACR Convergence in November, while CLN-978 data in SLE, rheumatoid arthritis and Sjögren's disease and updated P
Read more
Report
Cullinan Therapeutics, Inc. Outlines Plans To Share CLN-978, Velinotamig And CLN-049 Pipeline Updates In Fourth Quarter 2026
Read more
Report
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release - Has The Bull Case Changed?
Taiho Pharmaceutical, Taiho Oncology and Cullinan Therapeutics recently reported that the Phase 3 REZILIENT3 trial of investigational EGFR inhibitor zipalertinib plus chemotherapy in previously untreated EGFR exon 20 insertion-positive advanced non-small
Read more
Report
Report
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Company to host a virtual event today at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modify
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Heidelberg
Germany
HQ